why choose us

First received: August 17, 2023

Clinical Trial: A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Refractory Solid Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Brief Summary: To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

Read more